Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 143

Sort by

Sort Order Select

Journal Articles

Numerous clinically-detected asciminib-resistant BCR::ABL1 mutations disrupt allostery and confer cross-resistance to the novel clinically-active allosteric TKI tgrx-678

Ariel Leyte-Vidal, Ian Outhwaite, Kaeli Miller, Emma Gebauer, Ailin Alvarez, Carlyn Leavitt, Nellie Ahmadieh, Brian Farrell, Isabelle Kwan, Susan Branford, Muneeza Maqsood, David Yeung, Timothy Hughes, Vivian Oehler, Delphine Rea, Ralf Landgraf, Ivette Bahar, Markus Seeliger, Neil Shah

Blood (2025) 146 (Supplement 1): 1516.

https://doi.org/10.1182/blood-2025-1516

Published: 2025

Journal Articles

Molecular landscape and clonal evolution in minor versus major BCR::ABL1 chronic myeloid leukemia under tyrosine kinase inhibition : A Study from the french group fi-LMC

Blood (2025) 146 (Supplement 1): 77.

https://doi.org/10.1182/blood-2025-77

Published: 2025

Journal Articles

Asciminib and pregnancy in CML: Preliminary human data and clinical implications from 47 reported outcomes

Elisabetta Abruzzese, Ekaterina Chelysheva, Delphine Rea, Katia Pagnano, Mohamed Yassin, Nithya Agrawal, Malgorzata Trawinska, Anna Turkina, Jane Apperley, Paolo De Fabritiis

Blood (2025) 146 (Supplement 1): 5566.

https://doi.org/10.1182/blood-2025-5566

Published: 2025

Journal Articles

CARDINAL: A Phase 1 study of TERN-701, a novel investigational allosteric BCR::ABL1 inhibitor for patients with previously treated CML

Elias Jabbour, Timothy Hughes, Richard Van Etten, David Andorsky, Gonzalo Carreño, Philipp le Coutre, Omer Jamy, Pilar Giraldo, Dong-Wook Kim, Vivian Oehler, Andreas Hochhaus, Jorge Cortes, Michael Mauro, Tonya Marmon, Leanne Holes, Emil Kuriakose, Hagop Kantarjian, Delphine Rea

Blood (2025) 146 (Supplement 1): 901.

https://doi.org/10.1182/blood-2025-901

Published: 2025

Journal Articles

A newcomer in allosteric therapy for Ph + leukemias

Delphine Rea

Blood (2025) 146 (17): 2016–2017.

https://doi.org/10.1182/blood.2025030565

Published: 2025

Journal Articles

Ponatinib Safety Profile: An Analysis of 10 Years of Real-World Experience

Elias Jabbour, Delphine Rea, Mouna Bardey-Kanaan, Romuald Soichez, Nhan Thanh Nguyen, Deborah Kelly, Federica Rizzo, Petros Patos, Valentín García Gutiérrez, Sr.

Blood (2024) 144 (Supplement 1): 3816.

https://doi.org/10.1182/blood-2024-200256

Published: 2024

Journal Articles

Cardinal: A Phase I, Multicenter, Open-Label, Dose-Escalation and Dose-Optimization Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Tern-701 in Chronic Myeloid Leukemia

Elias Jabbour, Delphine Rea, Jorge E. Cortes, Andreas Hochhaus, Timothy P Hughes, Dong-Wook Kim, Hagop M. Kantarjian, Leanne Holes, Emil T. Kuriakose, Michael J. Mauro

Blood (2024) 144 (Supplement 1): 6594.

https://doi.org/10.1182/blood-2024-204153

Published: 2024

Journal Articles

Retrospective Study to Compare Treatment Outcomes of Asciminib Vs. Ponatinib in 99 Patients with T315I Mutated Chronic Myeloid Leukemia

Blood (2024) 144 (Supplement 1): 3149.

https://doi.org/10.1182/blood-2024-205681

Published: 2024

Journal Articles

Asciminib Provides Long-Term, Durable Molecular Responses in Patients with T315I-Mutated CML-CP: Final Analysis from a Phase 1 Trial

Blood (2024) 144 (Supplement 1): 1765.

https://doi.org/10.1182/blood-2024-209537

Published: 2024

Journal Articles

BCR :: ABL1 kinase N-lobe mutants confer moderate to high degrees of resistance to asciminib

Ariel Leyte-Vidal, Diego Garrido Ruiz, RosaAnna DeFilippis, Inga B. Leske, Delphine Rea, Stacey Phan, Kaeli B. Miller, Feifei Hu, Anjeli Mase, Yibing Shan, Oliver Hantschel, Matthew P. Jacobson, Neil P. Shah

Blood (2024) 144 (6): 639–645.

https://doi.org/10.1182/blood.2023022538

Published: 2024

Journal Articles

With up to 8 Years of Therapy, Asciminib (ASC) Monotherapy Demonstrated Continued Favorable Efficacy, Safety, and Tolerability in Patients (Pts) with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase (Ph+ CML-CP) without the T315I Mutation: Final Results from the Phase 1 X2101 Study

Blood (2023) 142 (Supplement 1): 450.

https://doi.org/10.1182/blood-2023-187322

Published: 2023

Journal Articles

Mutation of Epigenetic Regulators at Diagnosis Is an Independent Predictor of Tyrosine Kinase Inhibitor Treatment Failure: A Report from the Residiag Study

Hippolyte Guerineau, Jean-Michel Cayuela, Stéphanie Dulucq, Violaine Tran Quang, Sihem Tarfi, Quentin Barathon, Corine Joy, Orianne Wagner-Ballon, Stéphane Morisset, Franck E. Nicolini, Lydia Roy, Sébastien Maury, Gabriel Etienne, Delphine Rea, Ivan Sloma

Blood (2023) 142 (Supplement 1): 4540.

https://doi.org/10.1182/blood-2023-186271

Published: 2023

Journal Articles

Asciminib (ASC) in Combination with Imatinib (IMA), Nilotinib (NIL), or Dasatinib (DAS) May be a Potential Treatment (Tx) Option in Patients (Pts) with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase or Accelerated Phase (Ph+ CML-CP/AP): Final Results from the Asciminib Phase 1 Study

Jorge Cortes, Fabian Lang, Delphine Rea, Andreas Hochhaus, Massimo Breccia, Yeow Tee Goh, Michael C. Heinrich, Timothy P Hughes, Jeroen J.W.M. Janssen, Philipp le Coutre, Hironobu Minami, Koji Sasaki, Daniel J. DeAngelo, Gessami Sanchez-Olle, Nathalie Pognan, Jomy Jose, Matthias Hoch, Michael Mauro

Blood (2023) 142 (Supplement 1): 868.

https://doi.org/10.1182/blood-2023-189270

Published: 2023

Journal Articles

Impact of Mutations in Blood Cancer-Related Genes on Clinical Outcomes in Chronic Myeloid Leukemia in Chronic Phase (CML-CP) after ≥2 Tyrosine Kinase Inhibitors (TKIs) in the Ascembl Trial

Susan Branford, Andreas Hochhaus, Michael Mauro, Yosuke Minami, Delphine Rea, Carla Maria Boquimpani De Moura Freitas, Pablo Serrano-Fernandez, Vanessa Obourn, Andreas Bruederle, Noemi Espurz, Timothy P Hughes

Blood (2023) 142 (Supplement 1): 449.

https://doi.org/10.1182/blood-2023-187636

Published: 2023

Journal Articles

Sustained Efficacy and Safety with Asciminib (ASC) after Almost 4 Years of Median Follow-up from Ascembl, a Phase 3 Study of ASC Vs Bosutinib (BOS) in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) after ≥2 Prior Tyrosine Kinase Inhibitors (TKIs): An End of Study Treatment (EOS Tx) Update, Including Results from Switch Population

Blood (2023) 142 (Supplement 1): 4536.

https://doi.org/10.1182/blood-2023-186854

Published: 2023

Journal Articles

Characteristics, Outcomes, Tfr Rates in Young Adults with Chronic Myeloid Leukemia in the Tyrosine Kinase Inhibitor Era: A French Observational Study

Blood (2023) 142 (Supplement 1): 1800.

https://doi.org/10.1182/blood-2023-173132

Published: 2023

Journal Articles

Propensity Score Matching Comparing Asciminib Versus Ponatinib in Chronic Myeloid Leukemia Patients Who Failed Prior Tyrosine Kinase Inhibitor Therapy

Maria Agustina Perusini, Camille Kockerols, Daniela Žáčková, Franck E. Nicolini, Fausto Castagnetti, Carolina Pavlovsky, Massimo Breccia, Delphine Rea, Carmen Fava, Mary Lynn Savoie, Christophe Bouvier, Petra Čičátková, Julien Bollard, Swe Mar Linn, Gopila Gupta, Emilia Scalzulli, Jiří Mayer, Peter E Westerweel, Dennis Dong Hwan Kim

Blood (2023) 142 (Supplement 1): 6360.

https://doi.org/10.1182/blood-2023-190293

Published: 2023

Journal Articles

Treatment-Free Remission after Ponatinib Cessation in Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Patients. the Ponastop Observational Study

Franck E. Nicolini, Elisabetta Abruzzese, Gabrielle Roth-Guepin, Rami Abi-Tayeh, Vincent Alcazer, Sandrine Hayette, Stéphane Morisset, Françoise Huguet, Miriam Iezza, Fausto Castagnetti, Delphine Rea

Blood (2023) 142 (Supplement 1): 1799.

https://doi.org/10.1182/blood-2023-178326

Published: 2023

Journal Articles

Dynamics of Response and Response Factors in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) after ≥2 Prior Tyrosine Kinase Inhibitors (TKIs) in the Phase 3 Ascembl Study

Timothy Hughes, Delphine Rea, Carla Boquimpani, Yosuke Minami, Michael Mauro, Jorge E. Cortes, Jane F. Apperley, Valentín García Gutiérrez, Shruti Kapoor, Alex Allepuz, Sarah Quenet, Yifan Zhang, Andreas Hochhaus

Blood (2022) 140 (Supplement 1): 6757–6759.

https://doi.org/10.1182/blood-2022-169110

Published: 2022

Journal Articles

A Risk Model for CML Patients with COVID-19: Importance of Molecular Response in the Context of Age, Comorbidities and Country Income

Jerald P. Radich, Chung Hoow Kok, Ekaterina Yu. Chelysheva, Jorge E. Cortes, Qian Jiang, Michael Mauro, Dragana Milojkovic, Beatriz Moiraghi, Franck E. Nicolini, Matilda Ongondi, Katia B Pagnano, Daniela Žácková, Delphine Rea, Nicola Evans, Timothy Hughes

Blood (2022) 140 (Supplement 1): 9617–9619.

https://doi.org/10.1182/blood-2022-165855

Published: 2022

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Numerous clinically-detected asciminib-resistant BCR::ABL1 mutations disrupt allostery and confer cross-resistance to the novel clinically-active allosteric TKI tgrx-678

Molecular landscape and clonal evolution in minor versus major BCR::ABL1 chronic myeloid leukemia under tyrosine kinase inhibition : A Study from the french group fi-LMC

Asciminib and pregnancy in CML: Preliminary human data and clinical implications from 47 reported outcomes

CARDINAL: A Phase 1 study of TERN-701, a novel investigational allosteric BCR::ABL1 inhibitor for patients with previously treated CML

A newcomer in allosteric therapy for Ph + leukemias

Ponatinib Safety Profile: An Analysis of 10 Years of Real-World Experience

Cardinal: A Phase I, Multicenter, Open-Label, Dose-Escalation and Dose-Optimization Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Tern-701 in Chronic Myeloid Leukemia

Retrospective Study to Compare Treatment Outcomes of Asciminib Vs. Ponatinib in 99 Patients with T315I Mutated Chronic Myeloid Leukemia

Asciminib Provides Long-Term, Durable Molecular Responses in Patients with T315I-Mutated CML-CP: Final Analysis from a Phase 1 Trial

BCR :: ABL1 kinase N-lobe mutants confer moderate to high degrees of resistance to asciminib

Mutation of Epigenetic Regulators at Diagnosis Is an Independent Predictor of Tyrosine Kinase Inhibitor Treatment Failure: A Report from the Residiag Study

Impact of Mutations in Blood Cancer-Related Genes on Clinical Outcomes in Chronic Myeloid Leukemia in Chronic Phase (CML-CP) after ≥2 Tyrosine Kinase Inhibitors (TKIs) in the Ascembl Trial

Characteristics, Outcomes, Tfr Rates in Young Adults with Chronic Myeloid Leukemia in the Tyrosine Kinase Inhibitor Era: A French Observational Study

Propensity Score Matching Comparing Asciminib Versus Ponatinib in Chronic Myeloid Leukemia Patients Who Failed Prior Tyrosine Kinase Inhibitor Therapy

Treatment-Free Remission after Ponatinib Cessation in Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Patients. the Ponastop Observational Study

Dynamics of Response and Response Factors in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) after ≥2 Prior Tyrosine Kinase Inhibitors (TKIs) in the Phase 3 Ascembl Study

A Risk Model for CML Patients with COVID-19: Importance of Molecular Response in the Context of Age, Comorbidities and Country Income

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only